| Name | Title | Contact Details |
|---|
AI REV is a boutique AI consulting company with partners having extensive practical AI experience and strong track records. We provide state-of-the-art consulting & AI project delivery for enterprise clients. AI REVs goal is to reduce the average human workweek from 40 hours to 20. We are working towards achieving this by augmenting companies with AI-powered efficiency improvements. Our solutions have saved our customers up to 25% on related departamental costs, substantially decreased their operational risk, and enabled the reallocation of manpower to more pressing issues. We offer end-to-end Machine Learning, Data Science, AI & software development, Strategic Consulting, and Engineering Workshops.
Valent Partners are an integrated team of strategists, business leaders and technologists obsessed with helping our clients reach new heights. We approach each situation through a holistic business and technology lens, advising on and delivering solutions that help your organization adapt ahead of your competition. You have a goal. Well get you there. If your organization is interested in finding ways that technology can improve your performance, profitability, and growth, we can help. Contact Valent Partners today to arrange a consultation on the challenges you face. Your Digital Journey begins here.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.
Since 1998, Euro Motors set out to position itself as the leader in the automotive industry in the Kingdom of Bahrain and has since come a long way. From a modest start with only BMW, the dealership has managed to acquire premium brands such as MINI, Land Rover, Jaguar, Rolls Royce, Ferrari and Maserati under its impressive banner. In doing so, it has preserved each identity with the utmost integrity and dedication.